 ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the Autorité des Marchés Financiers AMF and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission SEC. 